Related Experiment Video
Updated: Jul 11, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Multi omics analysis of mitophagy subtypes and integration of machine learning for predicting immunotherapy responses
Junzhi Liu1, Huimin Li2, Qiuping Dong2
1Department of Otorhinolaryngology, Tianjin Medical University General Hospital, Tianjin 300052, China.
Abstract:
Mitophagy serves as a critical mechanism for tumor cell death, significantly impacting the progression of tumors and their treatment approaches. There are significant challenges in treating patients with head and neck squamous cell carcinoma, underscoring the importance of identifying new targets for therapy. The function of mitophagy in head and neck squamous carcinoma remains uncertain, thus investigating its impact on patient outcomes and immunotherapeutic responses is especially crucial. We initially analyzed the differential expression, prognostic value, intergene correlations, copy number variations, and mutation frequencies of mitophagy-related genes at the pan-cancer level. Through unsupervised clustering, we divided head and neck squamous carcinoma into three subtypes with distinct prognoses, identified the signaling pathway features of each subtype using ssGSEA, and characterized subtype B as having features of an immune desert using various immune infiltration calculation methods. Using multi-omics data, we identified the genomic variation characteristics, mutated gene pathway features, and drug sensitivity features of the mitophagy subtypes. Utilizing a combination of 10 machine learning algorithms, we have developed a prognostic scoring model called Mitophagy Subgroup Risk Score (MSRS), which is used to predict patient survival and the response to immune checkpoint blockade therapy. Simultaneously, we applied MSRS to single-cell analysis to explore intercellular communication. Through laboratory experiments, we validated the biological function of SLC26A9, one of the genes in the risk model. In summary, we have explored the significant role of mitophagy in head and neck tumors through multi-omics data, providing new directions for clinical treatment.
Insights
Mitophagy, a cell death process, impacts head and neck squamous cell carcinoma (HNSCC) progression and treatment. This study developed a risk score (MSRS) to predict HNSCC patient survival and immunotherapy response.
Area of Science:
- Oncology
- Cell Biology
- Genomics
Background:
- Mitophagy is crucial for tumor cell death but its role in head and neck squamous cell carcinoma (HNSCC) is unclear.
- Effective HNSCC treatment is challenging, necessitating novel therapeutic targets.
- Understanding mitophagy's impact on HNSCC outcomes and immunotherapy is vital.
Purpose of the Study:
- To investigate the role of mitophagy in HNSCC.
- To identify mitophagy-related subtypes and their prognostic significance.
- To develop a predictive model for HNSCC patient survival and immunotherapy response.
Main Methods:
- Pan-cancer analysis of mitophagy genes, unsupervised clustering for HNSCC subtypes, ssGSEA for pathway analysis, immune infiltration analysis.
- Multi-omics data analysis for genomic variations, mutated gene pathways, and drug sensitivity.
- Development and validation of a prognostic scoring model (MSRS) using machine learning and laboratory experiments.
Main Results:
- Identified three distinct HNSCC subtypes based on mitophagy, with one subtype characterized as an 'immune desert'.
- Developed the Mitophagy Subgroup Risk Score (MSRS) model to predict patient survival and response to immune checkpoint blockade therapy.
- Validated the biological function of SLC26A9, a key gene in the MSRS model, through laboratory experiments.
Conclusions:
- Mitophagy plays a significant role in HNSCC, influencing patient prognosis and immune evasion.
- The MSRS model offers a novel tool for predicting outcomes and guiding immunotherapy in HNSCC patients.
- This research provides new therapeutic strategies for HNSCC by targeting mitophagy pathways.

